Development and Validation of Three Triplex Real-Time RT-PCR Assays for Typing African Horse Sickness Virus: Utility for Disease Control and Other Laboratory Applications

Viruses. 2024 Mar 20;16(3):470. doi: 10.3390/v16030470.

Abstract

The African horse sickness virus (AHSV) belongs to the Genus Orbivirus, family Sedoreoviridae, and nine serotypes of the virus have been described to date. The AHSV genome is composed of ten linear segments of double-stranded (ds) RNA, numbered in decreasing size order (Seg-1 to Seg-10). Genome segment 2 (Seg-2) encodes outer-capsid protein VP2, the most variable AHSV protein and the primary target for neutralizing antibodies. Consequently, Seg-2 determines the identity of the virus serotype. An African horse sickness (AHS) outbreak in an AHS-free status country requires identifying the serotype as soon as possible to implement a serotype-specific vaccination program. Considering that nowadays 'polyvalent live attenuated' is the only commercially available vaccination strategy to control the disease, field and vaccine strains of different serotypes could co-circulate. Additionally, in AHS-endemic countries, more than one serotype is often circulating at the same time. Therefore, a strategy to rapidly determine the virus serotype in an AHS-positive sample is strongly recommended in both epidemiological situations. The main objective of this study is to describe the development and validation of three triplex real-time RT-PCR (rRT-PCR) methods for rapid AHSV serotype detection. Samples from recent AHS outbreaks in Kenia (2015-2017), Thailand (2020), and Nigeria (2023), and from the AHS outbreak in Spain (1987-1990), were included in the study for the validation of these methods.

Keywords: African horse sickness; diagnostic; real-time RT-PCR; serotypes; vaccination.

MeSH terms

  • African Horse Sickness Virus*
  • African Horse Sickness* / diagnosis
  • African Horse Sickness* / epidemiology
  • African Horse Sickness* / prevention & control
  • Animals
  • Antibodies, Neutralizing
  • Horses
  • Orbivirus* / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Viral Vaccines*

Substances

  • Antibodies, Neutralizing
  • Viral Vaccines

Grants and funding

This research was funded by European Commission grant number Project 101144079—EURL-AHS-BT 2023–2024, and the Ministry of Agriculture, Fisheries and Food (MAPA), Spain, through the budget assigned for the periods 2023 and 2024.